



Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

	URGENT	
MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE: ZIP CODE:	
PATIENT INSURANCE ID NUMBER:		
MALE FEMALE HEIGHT (IN/CM): WEIG	HT (LB/KG): ALLERGIES:	

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF</u>

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:		
		THERAPY/REFILLS:			
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.









MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
 Primary hypercholesterolemia mixed dyslipidemia Fredrickson types IIa and IIb hypertriglyceridemia Fredrickson types IV and V hyperlip 	pidemia	
Other diagnosis:ICD-	10	
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A
Clinical Information:		
 135 mg, 45 mg, 105 mg, 35 mg Is the patient taking fenofibrat Does the patient have a docum listed above? Yes No Has the patient had an inadequivalues while on one of the prefixed 	e with food? Yes No nented intolerance or side effect to a one uate response as documented by higher ferred generic fenofibrates listed above f oses, symptoms, medications tried or fa	e of the preferred generic fenofibrates than normal triglycerides (TG) lab ? □ Yes □ No
information is received. ATTESTATION: I attest the information the Health Plan, insurer, Medical Group information necessary to verify the acc	e covered on all plans. This request may n provided is true and accurate to the be o or its designees may perform a routine curacy of the information reported on thi	st of my knowledge. I understand that audit and request the medical is form.
	Verification:	
you are not the intended recipient, you are here	ompanying this transmission contain confidential eby notified that any disclosure, copying, distribut have received this information in error, please no se documents.	tion, or action taken in reliance on the contents
© 2017 – 2023 by Magellan Rx Management, LLC Revision Date: 02/01/2022 CAT0295	C. All Rights Reserved.	





Fenofibrate micronized Prior Authorization Request Form Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640



FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

